Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tradipitant: First Approval.

Drugs·2026
Same author

Depemokimab: First Approval.

Drugs·2026
Same author

Sibeprenlimab: First Approval.

Drugs·2026
Same author

Zongertinib: First Approval.

Drugs·2026
Same author

Rilzabrutinib: First Approval.

Drugs·2025
Same author

Dorocubicel: First Approval.

Molecular diagnosis & therapy·2025

相关实验视频

Updated: May 30, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

奥贝卡巴泰基因自杀剂:首次获得批准

Arnold Lee1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. mdt@adis.com.

Molecular diagnosis & therapy
|January 31, 2025
PubMed
概括

一种新的CD19定向免疫疗法Obecabtagene autoleucel获得了针对复发性或耐火性B细胞急性淋巴细胞白血病的批准. 这种CAR T疗法为CD19提供了一种独特的快速脱离率结合剂,简化了患者监测.

科学领域:

  • 免疫治疗是一种免疫疗法.
  • 血液瘤学 血液瘤学
  • 细胞疗法细胞疗法

背景情况:

  • 奥贝卡巴特基因自细胞 (AUCATZYL®) 是一种创新的CD19导向的转基因自T细胞免疫疗法.
  • 它是为血液癌症和全身性红斑狼开发的.

研究的目的:

  • 要总结obecabtagene autoleucel. 的发展里程碑.
  • 为突出其首次批准成人患者复发或耐火B细胞前体急性淋巴细胞白血病 (ALL).

主要方法:

  • 发展途径导致监管部门的批准.
  • 评估临床试验数据,包括FELIX I/II期试验.

主要成果:

  • 在FELIX试验中,Obecabtagene autoleucel在患有复发性或耐火性B细胞ALL的成年人中显示出积极的结果.
  • 它是第一个没有强制性风险评估和缓解策略监测的仿真抗原受体T (CAR T) 疗法.

结论:

  • 奥贝卡巴特基因自细胞代表了对B细胞ALL的CAR-T疗法的重大进展.
  • 它的独特特性,包括快速的离速粘合剂和没有强制性监测,使其成为一个有前途的治疗选择.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.4K

相关实验视频

Last Updated: May 30, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.4K